A Novel Prediction Model for Significant Liver Fibrosis in Patients with Chronic Hepatitis B
Table 1
Parameters of patients with chronic hepatitis B.
Training set ()
Validation set ()
Age (year)
0.003
Gender (male/female)
160/92
98/70
0.288
ALT (U/L)
46.0 (26.0-114.5)
49.0 (24.0-101.0)
0.841
AST (U/L)
36.0 (24.0-64.75)
38.0 (25.0-71.75)
0.406
TBIL (μmol/L)
14.5 (10.6-18.8)
14.0 (8.9-23.1)
0.803
ALB (g/L)
45.4 (41.4-47.2)
43.4 (41.5-46.1)
0.363
PLT (×109/L)
186.0 (151.0-232.0)
183.0 (133.25-226.5)
0.188
HA (ng/mL)
40.98 (26.08-72.19)
48.16 (31.56-91.28)
0.016
LN (ng/mL)
53.03 (41.91-65.00)
49.73 (41.62-62.35)
0.266
IVC (ng/mL)
48.72 (28.79-81.04)
56.99 (33.63-106.02)
0.115
PIIINP (ng/mL)
10.77 (7.39-17.43)
11.04 (7.85-16.8)
0.472
HBeAg (+/-)
91/161
42/126
HBeAb (+/-)
119/133
60/108
Inflamation,G0/G1/G2/G3/G4,
28/130/70/23/1
11/75/66/15/1
Liver biopsy ()
94/158
82/86
0.021
Stage of fibrosis, S0/S1/S2/S3/S4,
35/138/46/23/10
13/72/44/33/6
Liver biopsy ()
79/173
83/85
0.001
ALT: alanine aminotransferase; AST: aspartate aminotransferase; TBIL: total bilirubin; ALB: albumin; PLT: blood platelet; HA: hyalurona; LN: laminin; IVC: type IV collagen; PIIINP: procollagen type III N-terminal peptide; HBeAg: hepatitis B e antigen; HBeAb: hepatitis B e antibody; : significant liver fibrosis; : no or mild liver fibrosis.
